/Dexcom%20Inc%20HQ-by%20JHVEPhoto%20via%20Shutterstock.jpg)
DexCom (DXCM) shares have put together an encouraging short-term bounce as the company maps out a multi-year growth algorithm. The stock currently carries a 8% “Sell” rating, but that’s up from the...
Dexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists 1 . The new system will be available...
DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and...
The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -1.24%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.54%. June E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.91%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.83%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.30%. June E-mini S&P futures...
The S&P 500 Index ($SPX ) (SPY ) today is down -1.17%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.96%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.64%. June E-mini S&P futures...
/Dexcom%20Inc%20logo%20on%20phone%20-by%20T_Schneider%20via%20Shutterstock.jpg)
Although DexCom has significantly underperformed the broader market over the past year, Wall Street analysts continue to maintain a very bullish outlook on the company’s long-term growth prospects.
Will Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Date Reconstituted Operations and Innovation Committee Will Expand Mandate to Oversee Operations,...
Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call.
2 Mid-Cap Stocks with Impressive Fundamentals and 1 We Question